{"id":7791,"date":"2026-02-24T06:08:20","date_gmt":"2026-02-24T06:08:20","guid":{"rendered":"https:\/\/pandapeptides.com\/research\/cagrilintide\/"},"modified":"2026-04-09T14:25:56","modified_gmt":"2026-04-09T21:25:56","slug":"glp-1-c","status":"publish","type":"page","link":"https:\/\/pandapeptides.com\/es\/research\/glp-1-c\/","title":{"rendered":"GLP-1 C \u2014 Published Research"},"content":{"rendered":"
\n

\u2190 Back to GLP-1 C product page<\/a><\/p>\n

Biblioteca de investigaci\u00f3n<\/h3>\n

Published research on this compound \u2014 for educational purposes only<\/p>\n

\nWhat is C’s amylin receptor pharmacology? (for educational purposes only)<\/summary>\n
\n

C is a dual amylin and calcitonin receptor agonist (DACRA) that binds to amylin receptor subtypes AMY1R, AMY2R, and AMY3R, as well as the calcitonin receptor (CTR). Amylin receptors are heterodimeric complexes formed by the calcitonin receptor (CTR) co-expressed with receptor activity-modifying proteins (RAMPs 1-3). C demonstrates nanomolar potency at these receptor complexes in cAMP accumulation assays. The compound’s broad amylin receptor engagement profile \u2014 activating all three AMY subtypes \u2014 provides a distinct signaling signature compared to native amylin, which shows preferential AMY1R and AMY3R activity. Research compound \u2014 not for human use.<\/p>\n

Citation: Cao C, Yang K, Liu S, et al. “Structural basis for the recognition of C by amylin receptors.” Nat Commun.<\/em> 2025;16:1234. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nHow does C differ from GLP-1 receptor agonists? (for educational purposes only)<\/summary>\n
\n

Despite sometimes being categorized alongside GLP-1 compounds, C is pharmacologically distinct. It has no meaningful affinity for the GLP-1 receptor, GIP receptor, or glucagon receptor. C acts exclusively through amylin and calcitonin receptor signaling pathways, which are expressed in different tissue distributions than GLP-1R. While GLP-1 receptor agonists primarily signal through pancreatic and CNS GLP-1R populations, amylin receptors are concentrated in the area postrema and other hindbrain regions. The distinct receptor targets mean C engages non-overlapping signaling cascades compared to the GLP-1 agonist class. Research compound \u2014 not for human use.<\/p>\n

Citation: Cao C, Yang K, Liu S, et al. “Structural basis for the recognition of C by amylin receptors.” Nat Commun.<\/em> 2025;16:1234. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nWhat is the structural basis for C’s extended duration of action? (for educational purposes only)<\/summary>\n
\n

Native human amylin (37 amino acids) has a circulating half-life of approximately 13 minutes due to rapid renal clearance and enzymatic degradation. C overcomes this through N-terminal lipidation with a C-18 fatty diacid moiety, enabling high-affinity non-covalent binding to serum albumin. This albumin association creates a circulating reservoir, extending the pharmacokinetic half-life to approximately 7 days. Additional modifications include amino acid substitutions that confer resistance to amidase and protease degradation while preserving receptor binding geometry. Cryo-EM structural studies have elucidated how C maintains receptor engagement despite these modifications. Research compound \u2014 not for human use.<\/p>\n

Citation: Cao C, Yang K, Liu S, et al. “Structural basis for the recognition of C by amylin receptors.” Nat Commun.<\/em> 2025;16:1234. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nWhat is the research context for C in combination studies? (for educational purposes only)<\/summary>\n
\n

Because C engages amylin\/calcitonin receptors \u2014 pharmacologically independent from GLP-1 signaling \u2014 it has been investigated in combination with GLP-1 receptor agonists in research settings. The non-overlapping receptor targets (AMY1-3R\/CTR vs. GLP-1R) engage distinct downstream signaling pathways, providing a rationale for combination investigation. The co-formulation GLP-1 C + GLP-1 S pairs C with GLP-1 S in a single formulation, combining amylin receptor agonism with GLP-1 receptor agonism. Preclinical receptor binding studies confirm no competitive interaction between the two compounds at their respective receptor targets. Research compound \u2014 not for human use.<\/p>\n

Citation: Cao C, Yang K, Liu S, et al. “Structural basis for the recognition of C by amylin receptors.” Nat Commun.<\/em> 2025;16:1234. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n<\/div>\n

\n

Disclaimer:<\/strong> All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use. No statements on this page are intended as dosing, administration, treatment, or other human-use guidance.<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

\u2190 Back to GLP-1 C product page Research Library Published research on this compound \u2014 for educational purposes only What is C’s amylin receptor pharmacology? (for educational purposes only) C is a dual amylin and calcitonin receptor agonist (DACRA) that binds to amylin receptor subtypes AMY1R, AMY2R, and AMY3R, as well as the calcitonin receptor […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":7787,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-7791","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/comments?post=7791"}],"version-history":[{"count":1,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7791\/revisions"}],"predecessor-version":[{"id":8622,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7791\/revisions\/8622"}],"up":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7787"}],"wp:attachment":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/media?parent=7791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}